Optimer buys back rights to difimicin
USA-based biopharmaceutical firm Optimer Pharmaceuticals says that it has regained North American rights to its antibiotic difimicin (PAR-101/OPT-80) from Par Pharmaceuticals, with which it had been collaborating on the product's development. The transaction brings to a close the partnership that was first established in 2005 (Marketletters passim).
Under the terms of the buy-back deal, Optimer has paid Par a one-time fee of $20.0 million, and is obligated to make a $5.0 million milestone payment as well as to provide royalties on product sales, assuming successful commercialization. Currently, the drug is in a Phase IIb/III trial as a treatment for Clostridium difficile-associated diarrhea.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze